The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Multiple myeloma news at ASH 2020
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares developments in the multiple myeloma field that will be discussed at ASH 2020. This includes a focus on BCMA-targeted therapies, both targeted CAR-T cells and bispecific antibodies, as well as novel targets and therapeutics such as talquetamab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
